Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Sanofi SA — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.52 (market cap $3.62B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 26.3× iShares MSCI United Kingdom (FTSE)'s market cap, and Sanofi SA pays a 6.01% dividend while iShares MSCI United Kingdom (FTSE) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and Sanofi SA for 94 Days on average.
| EWU | SNY | |
|---|---|---|
Market Cap | $3.62B | $95.18B |
Volume | 923,896 | 2,995,646 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $52.34 |
52-Week Low | $41.34 | $39.51 |
Typical Hold Time | 46 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU trades at $46.23, up 0.65% on the day, but faces a bearish technical outlook with 16 sell signals versus 3 buy signals. The stock is testing key support at $46 amid rising UK gilt yields and inflation concerns. Recent UK housing policy announcements have boosted related sectors, but broader European economic pressures and ECB rate hikes create headwinds for the UK-focused ETF.
The outlook remains cautious given technical weakness and macroeconomic pressures from rising interest rates and energy prices. Investment opportunity exists if housing stimulus gains traction, but risks include prolonged inflation and further ECB tightening that could pressure UK equities.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
